SMC Issues Positive Decision for Treatment with AbbVie’s RINVOQ®▼(upadacitinib) in Severe Active Rheumatoid Arthritis (RA) February 19, 2021 Positive indication means upadacitinib will be available to those with previously treated severe active RA* SMC approval is based on data from pivotal Ph... Read More... FeaturedNews 0
